2-isopropyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-isopropyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
• 英文别名: 2-propan-2-yl-3H-1,2-benzothiazole 1,1-dioxide
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.285
• InChiKey: GOBALRSQICODFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-碘苄醇 在 manganese(IV) oxide 、 potassium pyrosulfite 、 三正丁胺 、 palladium diacetate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 14.0h， 生成 2-isopropyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide
  参考文献：
  名称：

  以K 2 S 2 O 5为二氧化硫替代物的Pd催化选择性合成环状磺酰胺和亚磺酰胺

  摘要：

  在Pd催化下，使用带有氨基的卤代芳烃和二氧化硫（SO 2）替代物可以选择性合成各种环状磺酰胺和亚磺酰胺。碱的量是决定选择性的关键。机理研究表明，亚硫酰胺最初是通过空前的一氧化硫形式化插入而形成的，并在存在碘离子和DMSO的情况下被氧化为磺酰胺。

  DOI：

  10.1021/acs.orglett.7b00402

文献信息

• [EN] PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA PIPÉRIDINONE EN TANT QU'INHIBITEURS DE MDM2 POUR LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2011153509A1

  公开（公告）日：2011-12-08

  The present invention provides MDM2 inhibitor compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式（I）的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于癌症的治疗。本发明还涉及含有MDM2抑制剂的药物组合物。
• PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：BARTBERGER Michael David

  公开号：US20110319378A1

  公开（公告）日：2011-12-29

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了公式I的MDM2抑制剂化合物，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
  申请人：AMGEN INC.

  公开号：US20160137667A1

  公开（公告）日：2016-05-19

  The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式I的MDM2抑制剂化合物，其中变量如上所定义，该化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的制药组合物。
• Cyclization Reactions of 2-Methylbenzenesulfonamides Using N,N-Dimethylcarbamoyl Chloride, N,N-Dimethylthiocarbamoyl Chloride, and N,N-Dimethylsulfamoyl Chloride
  作者：Masahiko Takahashi、Tomoya Morimoto、Ken-ichi Isogai、Sousi Tsuchiya、Keisuke Mizumoto

  DOI：10.3987/com-01-9287

  日期：——

  Generation of C,N-dianions (2) of 2-methylbenzenesulfonamides (1) followed by addition of N,N-dimethylcarbamoyl chloride gave 2-(N,N-dimethylcarbamoyl)methylbenzenesulfonamides (3), which were cyclized to 3,4-dihydro-2H-1,2-benzo[e]thiazin-3-one 1,1-dioxides (5). 3-Dimethylamino-2H-1,2-benzo)[e]thiazine. 1,1-dioxides (7) were obtained in one step by the reaction of 2 with N,N-dimethylthiocarbamoyl chloride. On the other hand, the reaction of 2 with N,N-dimethylsulfamoyl chloride yielded 2,2 ' -ethylene-bis(benzenesulfonamide)s (10) and / or 2,3-dihydro-1,2-benzothiazole 1,1-dioxides (11).
• PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND
  申请人：Kato Issei

  公开号：US20120135997A1

  公开（公告）日：2012-05-31

  The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid β proteins. The present invention provides a pharmaceutical composition for suppressing amyloid β production comprising a compound of the formula: wherein A is a benzene ring, a pyridine ring or a pyrimidine ring, X is sultam, lactam, sulfonamide or the like, C is substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl or the like, R 2 , R 3 and R 4 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or the like, its pharmaceutically acceptable salt or a solvate thereof.